Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social & Governance
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News

News & Views

Latest News

Category: News

See all

FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Events, News,

Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is...

Read more

Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented in “Game Changing” Session at EAU

Events, News,

Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...

Read more

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Events, News,

Telix today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held...

Read more

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

ASX, News,

Telix today announces its financial results for the financial year ended 31 December...

Read more

Webcast of Investor Briefing: ASCO GU ZIRCON Phase III Results Presentation

Events, News,

Telix is pleased to provide a webcast recording of A/Prof Brian Shuch and Dr Colin Hayward, Telix Group Chief Medical Officer. The briefing provided an opportunity for investors to hear...

Read more

Telix 2022 Full Year Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Full Year Results and Annual Report for the period ended 31 December 2022 on Monday 27 February 2023 at market...

Read more

Detailed Results from Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

Clinical, News,

Telix today announces detailed positive results from its completed pivotal Phase III ZIRCON trial (ClinicalTrials.gov Identifier: NCT03849118)1. The study met primary and secondary endpoints, with TLX250-CDx demonstrating the ability to...

Read more

Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine

Clinical, News,

Telix today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.1 The aim of this...

Read more

Notification of Investor Briefing: ASCO-GU ZIRCON Phase III Results Presentation

ASX, News,

Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study...

Read more

Activities Report and Appendix 4C for December quarter

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise...

Read more

Posts navigation

1 2 … 27

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au